Drug
Barzolvolimab
Barzolvolimab: highest development phase Phase 3, developed by Celldex Therapeutics. 8 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Celldex Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| barzolvolimab NCT07256392 | Phase 3 | Chronic Spontaneous Urticaria |
| barzolvolimab NCT06455202 | Phase 3 | Chronic Spontaneous Urticaria |
| Barzolvolimab NCT07266402 | Phase 3 | Chronic Inducible Urticaria |
| barzolvolimab NCT06445023 | Phase 3 | Chronic Spontaneous Urticaria |
| barzolvolimab NCT05368285 | Phase 2 | Chronic Spontaneous Urticaria |
| Barzolvolimab NCT06727552 | Phase 2 | Atopic Dermatitis |
| barzolvolimab NCT05405660 | Phase 2 | Chronic Inducible Urticaria |
| barzolvolimab NCT06366750 | Phase 2 | Prurigo Nodularis |
Latest
No recent events.
Follow Barzolvolimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.